Option Care Health (NASDAQ:OPCH – Get Free Report) had its price target boosted by equities researchers at JPMorgan Chase & Co. from $38.00 to $40.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 31.88% from the stock’s previous close.
A number of other brokerages have also issued reports on OPCH. The Goldman Sachs Group lowered Option Care Health from a “buy” rating to a “neutral” rating and cut their price target for the stock from $38.00 to $27.00 in a research note on Monday, November 4th. JMP Securities reissued a “market outperform” rating and set a $30.00 target price (down previously from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. UBS Group assumed coverage on Option Care Health in a research note on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target for the company. Barrington Research lifted their price objective on shares of Option Care Health from $32.00 to $33.00 and gave the company an “outperform” rating in a research report on Tuesday, January 14th. Finally, Jefferies Financial Group upgraded shares of Option Care Health from a “hold” rating to a “buy” rating and upped their target price for the stock from $26.00 to $35.00 in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Option Care Health has an average rating of “Moderate Buy” and an average target price of $32.25.
View Our Latest Analysis on Option Care Health
Option Care Health Stock Performance
Insider Activity at Option Care Health
In related news, Director Harry M. Jansen Kraemer, Jr. acquired 43,000 shares of Option Care Health stock in a transaction on Friday, November 8th. The shares were bought at an average cost of $22.54 per share, with a total value of $969,220.00. Following the completion of the purchase, the director now directly owns 326,334 shares of the company’s stock, valued at $7,355,568.36. The trade was a 15.18 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.64% of the stock is owned by insiders.
Hedge Funds Weigh In On Option Care Health
A number of institutional investors and hedge funds have recently modified their holdings of the stock. UMB Bank n.a. raised its holdings in Option Care Health by 937.5% during the 3rd quarter. UMB Bank n.a. now owns 830 shares of the company’s stock valued at $26,000 after buying an additional 750 shares during the period. GAMMA Investing LLC raised its stake in shares of Option Care Health by 110.6% in the third quarter. GAMMA Investing LLC now owns 897 shares of the company’s stock valued at $28,000 after acquiring an additional 471 shares during the period. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Option Care Health by 3,362.8% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 1,489 shares of the company’s stock valued at $47,000 after acquiring an additional 1,446 shares during the period. International Assets Investment Management LLC lifted its holdings in shares of Option Care Health by 3,029.7% in the 3rd quarter. International Assets Investment Management LLC now owns 2,848 shares of the company’s stock worth $91,000 after acquiring an additional 2,757 shares during the last quarter. Finally, Quarry LP boosted its stake in shares of Option Care Health by 327.7% during the 3rd quarter. Quarry LP now owns 3,430 shares of the company’s stock worth $107,000 after purchasing an additional 2,628 shares during the period. Hedge funds and other institutional investors own 98.05% of the company’s stock.
About Option Care Health
Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
Read More
- Five stocks we like better than Option Care Health
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Bloom Energy: Powering the Future With Decentralized Energy
- Find and Profitably Trade Stocks at 52-Week Lows
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- 3 Warren Buffett Stocks to Buy Now
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.